NeuBase Therapeutics

About:

NeuBase Therapeutics develops gene silencing therapies with its synthetic antisense oligonucleotides.

Website: https://www.neubasetherapeutics.com/

Twitter/X: neubaseinc

Description:

NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company that develops gene silencing therapies with its synthetic antisense oligonucleotides. It also provides a platform that focuses on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy, and Familial Parkinson's Disease, among others.

Total Funding Amount:

$14M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Pittsburgh, Pennsylvania, United States

Founded Date:

2009-08-04

Contact Email:

info(AT)neubasetherapeutics.com

Founders:

Dietrich Stephan

Number of Employees:

11-50

Last Funding Date:

2023-06-28

IPO Status:

Public

Industries:

© 2025 bioDAO.ai